Clinical Trials
209 trialsSTELLAR-002
Exelixis
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
ProTACT
Full-Life Technologies GmbH
NEXUS-01
Eli Lilly and Company
OMNIRAY
Eli Lilly and Company
DK222 Study at Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SABRE
Children's National Research Institute
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
M.D. Anderson Cancer Center
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Institutes of Health Clinical Center (CC)
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Deciphera Pharmaceuticals, LLC
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Amgen
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
FORAGER-1
Eli Lilly and Company
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc
Drug Screening Using Novel IMD in Renal Cell Carcinoma
Brigham and Women's Hospital
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Genentech, Inc.
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences Ltd
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
TITER
EMD Serono
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Daiichi Sankyo
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Abramson Cancer Center at Penn Medicine
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Amgen
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
National Cancer Institute (NCI)
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
MRG003
Sun Yat-sen University
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
AstraZeneca
BActinium-1
Aktis Oncology, Inc.
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Memorial Sloan Kettering Cancer Center
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
M.D. Anderson Cancer Center
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Novartis
A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer
University of Wisconsin, Madison
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Amgen
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Bristol-Myers Squibb
A Study of GEN1106 in Participants With Solid Tumors
Genmab
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Janssen Research & Development, LLC
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
ARC-20
Arcus Biosciences, Inc.